<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01332786</url>
  </required_header>
  <id_info>
    <org_study_id>OZM-029</org_study_id>
    <nct_id>NCT01332786</nct_id>
  </id_info>
  <brief_title>Safety Study Evaluating Intravenous Infusions of Tigecycline to Treat Acute Myeloid Leukemia</brief_title>
  <official_title>Phase 1 Study Evaluating the Tolerance and Biologic Activity of Intravenous Infusions of Tigecycline in Patients With Relapsed or Refractory AML</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Kansas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether tigecycline is safe and which dosage is&#xD;
      most effective in the treatment of patients with acute myeloid leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Relapsed and refractory hematologic malignancies have poor responses to standard therapy and&#xD;
      are associated with a poor prognosis. For example, relapsed acute myeloid leukemia (AML) is a&#xD;
      highly aggressive and resistant disease, particularly when associated with first complete&#xD;
      response (CR) duration of less than 12 months. Thus, there is an urgent need for new agents&#xD;
      in relapsed and refractory hematologic malignancies such as acute leukemia. In elderly&#xD;
      patients, where the tolerance of aggressive induction therapy is often poor and curative&#xD;
      options such as bone marrow transplantation HSCT are not available, the need for effective&#xD;
      non-aggressive drug regimens for AML is even greater.&#xD;
&#xD;
      Tigecycline is a glycylcycline derivative of tetracycline. Tigecycline is currently indicated&#xD;
      for the treatment of complicated skin and skin structure infections, and complicated&#xD;
      intra-abdominal infections. This clinical trial is a Phase I dose escalation study of&#xD;
      tigecycline in patients with relapsed or refractory AML or those with newly diagnosed disease&#xD;
      not eligible for induction chemotherapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity evaluated according to CTCAE version 4.03</measure>
    <time_frame>Reviewed at each visit and assessed at the end of each 3-week cycle</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate assessment of tigecycline through laboratory assessments</measure>
    <time_frame>Assessed at the end of each 3-week cycle for the study duration</time_frame>
    <description>Bone marrow assessment, absolute neutrophil count, platelet counts</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Tigecycline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tigecycline</intervention_name>
    <description>Dosage Form: one-hour intravenous infusion Dosage levels, frequency, duration: (3-week cycles)&#xD;
Level 1: 50 mg daily x 10 doses; 1 week rest&#xD;
Level 2: 100 mg daily x 10 doses; 1 week rest&#xD;
Level 3: 150 mg daily x 10 doses; 1 week rest&#xD;
Level 4: 200 mg daily x 10 doses 1 week rest&#xD;
Level 5: 250 mg daily x 10 doses; 1 week rest&#xD;
Level 6: 300 mg daily x 10 doses; 1 week rest&#xD;
Level 7: 350 mg daily x 10 doses; 1 week rest</description>
    <arm_group_label>Tigecycline</arm_group_label>
    <other_name>Tygacil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;18 years&#xD;
&#xD;
          -  Diagnosis of relapsed or refractory AML for which all potentially curative or standard&#xD;
             salvage therapy options have been exhausted; OR AML without prior treatment who are&#xD;
             not eligible for induction chemotherapy as defined as age &gt; or equal to 80 or age &gt; 70&#xD;
             with poor risk cytogenetics (3 or more abnormalities, -5/del(5q), 3q abnormalities, or&#xD;
             -7) or stable co-morbidities that would preclude induction chemotherapy such as LVEF&#xD;
             less than 40% and/or DlCO less than 60% expected&#xD;
&#xD;
          -  ECOG 0-2 performance status&#xD;
&#xD;
          -  Biochemical values within the following range&#xD;
&#xD;
          -  Serum creatinine &lt;2x upper limit of normal&#xD;
&#xD;
          -  Total bilirubin &lt;1.5x upper limit of normal&#xD;
&#xD;
          -  AST and ALT &lt;2x upper limit of normal&#xD;
&#xD;
          -  Recovery from non-hematologic toxicity from prior chemotherapy&#xD;
&#xD;
          -  Able and willing to provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allergy to tetracycline or minocycline&#xD;
&#xD;
          -  Uncontrolled intercurrent illness such as uncontrolled diabetes or active uncontrolled&#xD;
             infection&#xD;
&#xD;
          -  Active systemic bacterial, fungal, or viral infection&#xD;
&#xD;
          -  Concomitant use of linezolid or chloramphenicol that are known to inhibit&#xD;
             mitochondrial protein synthesis&#xD;
&#xD;
          -  Pregnant or breast feeding&#xD;
&#xD;
          -  Known active CNS involvement with AML&#xD;
&#xD;
          -  Neurologic symptoms related to uncontrolled illnesses or unexplained causes&#xD;
&#xD;
          -  Psychiatric illness that would limit compliance with study&#xD;
&#xD;
          -  Receiving systemic chemotherapy other than hydroxyurea to control circulating blast&#xD;
             counts. Concomitant hydroxyurea is permitted, but only in the first cycle of therapy&#xD;
&#xD;
          -  Prior therapy with tigecycline as an anti-cancer therapy or any use of the drug in the&#xD;
             last month&#xD;
&#xD;
          -  Use of other investigational anti-leukemic therapy within 14 days of registration&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aaron Schimmer, MD</last_name>
    <role>Study Director</role>
    <affiliation>University Health Network, Toronto</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <study_first_submitted>March 31, 2011</study_first_submitted>
  <study_first_submitted_qc>April 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2011</study_first_posted>
  <last_update_submitted>April 14, 2015</last_update_submitted>
  <last_update_submitted_qc>April 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AML</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tigecycline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

